Unravelling the distinct effects of VHL mutations and chromosome 3p loss in clear cell renal cell carcinoma: Implications for prognosis and treatment

Xiang Wang; Jian-Rong Li; Naail Raed Chowdhury; Lang Wu; Cheng Chao

doi:10.1002/ctm2.70465

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (10) : e70465 DOI: 10.1002/ctm2.70465

LETTER TO THE EDITOR

Unravelling the distinct effects of VHL mutations and chromosome 3p loss in clear cell renal cell carcinoma: Implications for prognosis and treatment

Author information +

History +

PDF

Cite this article

Download citation ▾

Xiang Wang, Jian-Rong Li, Naail Raed Chowdhury, Lang Wu, Cheng Chao. Unravelling the distinct effects of VHL mutations and chromosome 3p loss in clear cell renal cell carcinoma: Implications for prognosis and treatment. Clinical and Translational Medicine, 2025, 15(10): e70465 DOI:10.1002/ctm2.70465

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Rose TL, Kim WY. Renal cell carcinoma: a review. JAMA. 2024; 332: 1001-1010.

[2]	Ricketts CJ, De Cubas AA, Fan H, et al. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018; 23: 313-326.

[3]	Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018; 48: 812-830 e814.

[4]	Li T, Fan J, Wang B, et al. TIMER: a Web Server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017; 77: e108-e110.

[5]	Gad S, Sultan-Amar V, Meric JB, et al. Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Target Oncol. 2007; 2: 3-6.

[6]	Carlo MI, Manley B, Patil S, et al. Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell carcinoma. Kidney Cancer. 2017; 1: 49-56.

[7]	Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008; 14: 435-446.

[8]	Hudson TJ, Anderson W, Artez A, et al.; International Cancer Genome C. International network of cancer genome projects. Nature. 2010; 464: 993-998.

[9]	Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020; 38: 803-817 e804.

[10]	Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020; 26: 909-918.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.